Abstract
A new generation of drugs that target calcitonin gene-related peptide (CGRP) pathways offers a unique opportunity to explore the relationship between responder rates (RRs) and improvement in patient outcomes. The authors hypothesize a “tipping point” exists for patients with a ≥75% migraine response. They propose higher RRs reported in trials with CGRP inhibitory antibodies deliver not only a quantitative change in monthly headache days, but also a qualitative change in function, for a clinically meaningful subpopulation of patients.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1092-1095 |
| Number of pages | 4 |
| Journal | Headache |
| Volume | 58 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 1 2018 |
ASJC Scopus subject areas
- Neurology
- Clinical Neurology